What is the clinical evidence from this study?

Study design: Other. Population: Doxorubicin-induced cardiotoxicity (n=24). Intervention: Ezetimibe vs. Doxorubicin alone. Primary outcome: Serum cardiac troponin I (cTnI) levels (pg/mL) (p=<0.0001).

October 11, 2024F1000ResearchOpen Access

Unleashing the cardioprotective potential of Ezetimibe against Doxorubicin-induced cardiotoxicity in Wistar rats: Targeting oxidative stress and NF-κB-mediated inflammation

Q: What are the key findings of this study?

Pretreatment with Ezetimibe at 10 or 20 mg/kg significantly alleviated doxorubicin-induced cardiac damage in rats, markedly reducing serum levels of cTnI and NT-proBNP (p<0.001).

View Full Paper

Ask AI

Bookmark

Key result

Pretreatment with Ezetimibe at 10 or 20 mg/kg significantly alleviated doxorubicin-induced cardiac damage in rats, markedly reducing serum levels of cTnI and NT-proBNP (p<0.001).

Why the study?

Doxorubicin causes dose-dependent cardiotoxicity driven by oxidative stress and inflammation, prompting investigation into whether ezetimibe provides cardioprotective effects against doxorubicin-induced cardiotoxicity.

Does ezetimibe prevent doxorubicin-induced cardiotoxicity in Wistar rats?

Population

24 adult male Wistar rats

Comparison

Control vs DOX vs 10 mg/kg EZE plus DOX vs 20 mg/kg EZE plus DOX

Design

Animal experimental study

Authors

ASA. Sabry MAMohammed AH Jabarah AL-Zobaidy

Discussion

Member takes

Implication

EZE may attenuate DIC in animals; leaves open any clinical translation or human trials.

Structured PICO

Does ezetimibe prevent doxorubicin-induced cardiotoxicity in Wistar rats?

Population

24 adult male Wistar rats were utilized to evaluate the cardioprotective effects of Ezetimibe against Doxorubicin-induced cardiotoxicity over a 14-day period.

Intervention

Ezetimibe 10 mg/kg or 20 mg/kg dissolved in corn oil via oral gavage for 14 consecutive days, plus a single intraperitoneal injection of 15 mg/kg doxorubicin on the 12th day

Comparator

Doxorubicin alone (corn oil via oral gavage for 14 days plus single intraperitoneal injection of 15 mg/kg doxorubicin on the 12th day) and healthy control (corn oil via oral gavage for 14 days)

Outcome

Serum levels of cardiac injury biomarkers (cardiac troponin I and NT-proBNP) at 14 dayssurrogate

Main Result

Absolute Event Rate: 156.27% vs 564.32%

p-value: p=<0.0001

Ezetimibe mitigates doxorubicin-induced cardiotoxicity in rats by reducing oxidative stress and NF-κB-mediated inflammation.

Limitations

Animal model findings may not directly translate to human clinical outcomes
Cardiac function (e.g., via echocardiography) was not directly examined
Limited evidence establishing a direct cause-and-effect relationship between the proposed molecular mechanisms and the cardioprotective effects

Cite This Study

Sabry et al. (2024) studied Doxorubicin-induced cardiotoxicity (n=24). Ezetimibe vs. Doxorubicin alone was evaluated on Serum cardiac troponin I (cTnI) levels (pg/mL) (p=<0.0001). Pretreatment with Ezetimibe at 10 or 20 mg/kg significantly alleviated doxorubicin-induced cardiac damage in rats, markedly reducing serum levels of cTnI and NT-proBNP (p<0.001).

synapsesocial.com/papers/6a7a48c214b028facf0e4417 https://doi.org/10.12688/f1000research.156321.1

View Full Paper

Ask AI

Bookmark

Unleashing the cardioprotective potential of Ezetimibe against Doxorubicin-induced cardiotoxicity in Wistar rats: Targeting oxidative stress and NF-κB-mediated inflammation

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Unleashing the cardioprotective potential of Ezetimibe against Doxorubicin-induced cardiotoxicity in Wistar rats: Targeting oxidative stress and NF-κB-mediated inflammation

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider